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PAST
The current American Joint Committee on Cancer
(AJCC) classification system for stage III cutaneous mel-
anoma is heterogeneous, with 5-year melanoma-specific
survival rates ranging from 88% for stage IIIA disease to
24% for stage IIID disease. Currently, the stage III clas-
sification not only incorporates data from the N stage, but
also qualifies T data from the primary tumour such as
Breslow thickness and ulceration status. This takes into
account the fact that the risk of distant spread and subse-
quent death from melanoma for the stage III group is
dependent on the risk of hematogenous spread from a
deeply invading primary tumour, in addition to the disease
burden of the metastatic nodes. Extracapsular spread
(ECS), a well-known risk factor for locoregional recur-
rence in melanoma patients with macrometastatic disease,
is associated with a poor prognosis.1–3 Although ECS is a
biomarker for poor prognosis, it is not included in the
current AJCC classification system.
PRESENT
This multi-center retrospective cohort study of 515
patients with nodal metastases4 comprehensively analyzed
the clinical relevance of ECS as a biomarker in nodal
disease and demonstrated that ECS is the most important
prognostic indicator for both macroscopic and microscopic
disease, upstaging patients to the next echelon in a manner
comparable with ulceration of the primary. The authors
have devised a simplified clinically and surgically relevant
classification system for microscopic and macroscopic
stage III disease by replacing N stage with ECS status.
FUTURE
Extracapsular spread was an exclusion criterion for the
last two major phase 3 melanoma surgical trials,5,6 and the
authors suggest that ECS in sentinel node-positive patients
still may be an indication for lymphadenectomy to achieve
regional control of disease as well as for adjuvant systemic
therapy. In future versions of the AJCC guidelines, ECS
should be considered as an independent staging variable
pending further validation of its relevance.
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